Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

14.72 -0.22 (-1.47%)

Streaming Delayed Price Updated: 3:56 PM EDT, Sep 3, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	420,406
Open	14.94
Bid (Size)	14.71 (1,100)
Ask (Size)	14.73 (200)
Prev. Close	14.94
Today's Range	14.28 - 14.94
52wk Range	5.970 - 16.93
Shares Outstanding	42,052,980
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

4DMT to Participate in Upcoming Investor Conferences

August 25, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Announces New Employment Inducement Grants

August 14, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	+101.1%	+101.1%
1 Month	+45.9%	+45.9%
3 Month	+54.5%	+54.5%
6 Month	+64.8%	+64.8%
1 Year	+139.7%	+139.7%

More News

4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

August 13, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population

July 18, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4D Molecular Therapeutics (NASDAQ:FDMT) Q1 2026: Revenue Miss and Wider Losses Overshadow Phase 3 Progress ↗

May 07, 2026

Via Chartmill

4DMT Announces New Employment Inducement Grants

July 17, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists

June 30, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD

June 29, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital

June 29, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Announces New Employment Inducement Grants

June 12, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT to Participate in Upcoming Investor Conferences

May 27, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy ↗

May 16, 2026

Via MarketBeat

4DMT Announces New Employment Inducement Grants

May 15, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

May 07, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT to Participate in Upcoming Investor Conferences

May 04, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

March 18, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT to Participate in Upcoming Investor Meetings

March 16, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT to Participate in Upcoming Investor Conferences

February 19, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Announces New Employment Inducement Grants

February 13, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD

February 09, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Announces New Employment Inducement Grants

January 17, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Provides Company Update and Anticipated Development Milestones for 2026

January 07, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease

December 17, 2025

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Announces New Employment Inducement Grants

December 12, 2025

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 08, 2025

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is 4D Molecular Therapeutics, Inc. - Common Stock publicly traded?

Yes, 4D Molecular Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does 4D Molecular Therapeutics, Inc. - Common Stock trade on?

4D Molecular Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for 4D Molecular Therapeutics, Inc. - Common Stock?

The ticker symbol for 4D Molecular Therapeutics, Inc. - Common Stock is FDMT on the Nasdaq Stock Market

What is the current price of 4D Molecular Therapeutics, Inc. - Common Stock?

The current price of 4D Molecular Therapeutics, Inc. - Common Stock is 14.72

When was 4D Molecular Therapeutics, Inc. - Common Stock last traded?

The last trade of 4D Molecular Therapeutics, Inc. - Common Stock was at 09/03/26 03:56 PM ET

What is the market capitalization of 4D Molecular Therapeutics, Inc. - Common Stock?

The market capitalization of 4D Molecular Therapeutics, Inc. - Common Stock is 619.02M

How many shares of 4D Molecular Therapeutics, Inc. - Common Stock are outstanding?

4D Molecular Therapeutics, Inc. - Common Stock has 619M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.